Skip to main content
SpringerLink
Log in

Le cancer du sein localisé

  • Chapter
Thérapeutique du cancer

  • 762 Accesses

Résumé

L’incidence annuelle du cancer du sein est estimé à 110,3/100 000 dans l’Union européenne en 2006 [1]. Elle augmente en raison de la généralisation du dépistage et du vieillissement de la population. Bien que la mortalité soit en baisse avec une survie à long terme de l’ordre de 80 %, le cancer du sein demeure une cause de mortalité importante.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Kataja V, Castiglione M (2009) Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv10–iv14

    Article  Google Scholar 

  2. Société française de sénologie (2009) Institut National du Cancer. Recommandations Professionnelles Cancer du sein in situ

    Google Scholar 

  3. Rousseau C, Devillers A, sagan C et al. (2006) Monitoring to early response to neoadjuvant chemotherapy in stage II and III breast cancer bf (18F) fluorodeoxyglucose positron emission tomography. J Clin Oncol 24: 5366–5372

    Article  PubMed  Google Scholar 

  4. Goldstein NS, Decker D, Severson D et al. (2007) Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 110: 1687–1696

    Article  PubMed  CAS  Google Scholar 

  5. Mathieu MC, Rouzier R, Llombart-Cussac A et al. (2004) The poor responsiveness of infiltrating lobular breast carcinomas to neaoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 40: 342–351

    Article  PubMed  Google Scholar 

  6. Buzdar AU, Valero V, Ibrahim NK et al. (2007) Neaoadjuvant therapy with paclitaxel followed by 5-fluorouracile, epirubicin and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and date of additional patients treated with the same regimen. Clin Cancer Res 13: 228–233

    Article  PubMed  CAS  Google Scholar 

  7. Early Breast Cancer Trialists’Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717

    Article  Google Scholar 

  8. Paik S, Bryant J, Tan-Chiu E et al. (2000) HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991–1998

    Article  PubMed  CAS  Google Scholar 

  9. Hortobagyi GN (2005) Trastuzumab in the treatment of breast cancer. N Engl J Med 353: 1734–1736

    Article  PubMed  CAS  Google Scholar 

  10. Veronesi U, Boyle P, Goldhirsch A et al. (2005) Breast cancer. Lancet 365: 1727–1741

    Article  PubMed  Google Scholar 

  11. Martin M, Pienkowski T, Mackey J et al. (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352: 2302–2313

    Article  PubMed  CAS  Google Scholar 

  12. Henderson IC, Berry DA, Demetri GD et al. (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976–983

    Article  PubMed  CAS  Google Scholar 

  13. Campone M, Fumoleau P, Bourbouloux E et al. (2005) Taxanes in adjuvant breast cancer setting: which standard in Europe? Crit Rev Oncol Hematol 55: 167–175

    Article  PubMed  Google Scholar 

  14. Martin M et al. (2009) GEICAM 9805. Asco, poster 542

    Google Scholar 

  15. Jones S, Holmes FA, O’Shaughnessy J et al. (2009) Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol 27: 1177–1183. Epub 2009 Feb 9

    Article  PubMed  CAS  Google Scholar 

  16. Romond EH, Perez EA, Bryant J et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684

    Article  PubMed  CAS  Google Scholar 

  17. D Slamon et al. (2009) Présentation BCIRG 006. SABCS

    Google Scholar 

  18. Hayes DF, Thor AD, Dressler LG et al. (2007) Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357: 1496–14506

    Article  PubMed  CAS  Google Scholar 

  19. Ejlertsen B, Jensen MB, Nielsen KV et al. (2010) TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol 28: 984–990

    Article  PubMed  CAS  Google Scholar 

  20. Van de Vijver MJ, He YD, van’t Veer LJ et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999–2009

    Article  PubMed  Google Scholar 

  21. Reyal F, Pierga JY, Salmon RJ et al. (2010) Le point sur les signatures moléculaires dans le cancer du sein. Oncologie 12: 263–268

    Article  CAS  Google Scholar 

  22. Sotiriou C, Wirapati P, Loi S et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl cancer Inst 98: 262–272

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie médicale, Hôpital Avicenne, 125, route de Stalingrad, 93009, Bobigny, Cedex

    L. Zelek

  2. Service d’oncologie médicale, Hôpital Tenon, 4, rue de la Chine, 75020, Paris

    J. Gligorov

Authors
  1. L. Zelek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Gligorov
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France

About this chapter

Cite this chapter

Zelek, L., Gligorov, J. (2011). Le cancer du sein localisé. In: Thérapeutique du cancer. Springer, Paris. https://doi.org/10.1007/978-2-8178-0021-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0021-9_12

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0020-2

  • Online ISBN: 978-2-8178-0021-9

Publish with us

Policies and ethics

Search

Navigation